INTRODUCTION

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) and is considered to be diverse in terms of biological, clinical, and pathological features. The curative and survival rate was considerably enhanced in DLBCL patients by adding rituximab to CHOP (cyclophosphamide, rituximab, vincristine, doxorubicin, and prednisone) chemotherapy. However, poorer survival was also observed in some DLBCL patients under standard R-CHOP therapy. In recent decades, it has been revealed that long-noncoding RNAs (lncRNAs) significantly contribute to regulating several biological events, such as proliferation, differentiation, and tumor suppression. The dysregulated lncRNAs considerably contribute to cancer progression. The role of lncRNA was recently identified in DLBCL. It has been demonstrated that lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) sponged miR-195 to improve tumor progression and immune escape of DLBCL. Through the miR-34b-5p-GLI1 cascade, MYC-regulated nuclear paraspeckle assembly transcript 1 (NEAT1) increased DLBCL...
Another reported study has been revealed that the expression of lncRNA, i.e., PEG10 was elevated in DLBCL relative to the normal tissues, which could provide a novel therapeutic target for DLBCL. However, there is a lack of clarity regarding the prognostic role of lncRNAs in DLBCL. Furthermore, the predictive value of some prognostic factors varied after the introduction of rituximab, a CD20 monoclonal antibody, and highlighting the need to reevaluate the prognostic value of predictive factors.

Microarray analysis was used to identify lncRNAs, and OR2A1-AS1 were mostly decreased in DLBCL cell. Thus, the goal of this study was to determine the best OR2A1-AS1 index cutoff value in DLBCL patients, to validate OR2A1-AS1’s specific prognostic value, and to research relationship with the cell of origin categorization (COOC). We also looked into whether the OR2A1-AS1 index plays an effective role in DLBCL patients’ prognosis.

2 | MATERIALS AND METHODS

2.1 | Patient selection

The current study included 98 patients with diagnosed DLBCL from the First People’s Hospital of Wenling. We applied the Lymph2Cx assay using a NanoString gene expression platform on pretreatment tissues obtained from 98 patients with DLBCL. Correspondingly, 98 noncancerous lymph node tissues were collected. The research
project was authorized by the Institute Research Ethics Committee of First People’s Hospital of Wenling after all patients gave their informed consent in compliance with the Declaration of Helsinki’s standards. All patients agreed to donate their samples to this research and completed a consent form. RCHOP-like therapy was administered to all patients.

2.2 | Bioinformatics analysis

The Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) was used to obtain the GSE97336 dataset comprising lncRNA expression profiles. Microarray analysis was used to identify lncRNAs that were differentially expressed in CD19-positive B cells from OCI-ly1 and OCI-ly19 cells. The microarray type used in the investigation was GEO2R, which was obtained from GEO. ASHGASPO19110 (OR2A1-AS1) were mostly decreased in DLBCL cell compared with CD19-positive B cell.

2.3 | qRT-PCR evaluations

The OR2A1-AS1 expression levels of target genes were determined using a qRT-PCR. TRizol™ (Invitrogen) was used for extracting total RNA from tissue samples, and 1 μg RNA was utilized for cDNA synthesis using the Reverse Transcription Kit (Takara). The ABI ViiATM7Dx Real-Time PCR System (Life Technologies) was used to run the qRT-PCR using the SYBR Green Realtime PCR Master Mix Kit (Toyobo). Relative expression was normalized using GAPDH and expressed using the $2^{-\Delta\Delta CT}$ method.19 The underlined primers were used for the qRT-PCR: OR2A1-AS1, forward 5’-ACGTGCACAGACAAGCTAAAGA-3’ and reverse 5’-ATCATCCACGGGAGTGACGA-3’; GAPDH (internal reference), forward 5’-TGACTTTCAACAGCGACACCCA-3’ and reverse 5’-CACCCTGTGCTGATGCCAAA-3’. Primers were designed using Primer3Plus (http://www.primer3plus.com/cgi-bin/dev/ primer3plus.cgi).

2.4 | Statistical analysis

The primary endpoints of the current study were OS and PFS. GraphPad Prism 7 (La Jolla) was used for statistical evaluations. The Kaplan–Meier method was used to plot the survival curves, and the log-rank test was carried out to compare them. A two-tailed log-rank test was conducted to identify variations, and a statistically considerable variation was defined as $p < 0.05$.

3 | RESULTS

3.1 | Profiling of lncRNAs from the DLBCL cell

In the current study, CD19-positive B cells and DLBCL cells, i.e., OCI-ly1 and OCI-ly19 were designated to examined the lncRNAs expression level using GEO data microarray profiling. According to the Volcano curve, the expression of lncRNA between DLBCL cells and CD19-positive B cells has some differences, as shown in Figure 1A. In addition, the lncRNAs differential expression may significantly distinguish DLBCL (2.335) from CD19-positive B cells (11.87). The unsupervised hierarchical clustering analysis of differentially expressed lncRNAs revealed that the dysregulated lncRNAs expression patterns were distinguishable between the DLBCL cell and CD19-positive B cell, and ASHGASPO19110 (OR2A1-AS1) were mostly decreased in DLBCL cell compared with CD19-positive B cell (Figure 1B,C). In addition, Box plots showed normalized intensities from DLBCL cell and CD19-positive B cell (Figure 1D). Thus, we chose OR2A1-AS1 for further research.

3.2 | Decreased expression of OR2A1-AS1 in DLBCL patients

Considering 98 noncancerous lymph node tissues and 98 primary DLBCL tissues, RT-qPCR was conducted to evaluate the OR2A1-AS1 selected via Hiseq sequencing. The result showed that OR2A1-AS1 expression was considerably reduced 2.9 times in DLBCL tissues (Figure 2). Because of this, the existing study aimed to evaluate the clinical and experimental application of OR2A1-AS1 in DLBCL.

3.3 | Patient characteristics

Table 1 shows the clinicopathological features. Herein, qRT-PCR was run to evaluate the OR2A1-AS1 expression in the RCHOP-like cohort, which included non-GCB-like-DLBCL (109/256, 42.6%) and GCB-DLBCL (147/256, 57.4%). The OR2A1-AS1 index was found in non-GCB-like-DLBCL and GCB-DLBCL (Table 1).

3.4 | Prognosis of OR2A1-AS1

We explored the correlation between clinicopathological features and OR2A1-AS1 expression after validating OR2A1-AS1 overexpression. OR2A1-AS1 expression was substantially linked

![FIGURE 2 Decreased expression of OR2A1-AS1 in DLBCL patients. ***$p<0.001$](https://example.com/figure2.jpg)
with CHOP-like treatment, B-symptoms, stages, subtypes, performance status, and IPI in 256 samples (Table 2) but not with other clinicopathological characteristics, i.e., sex and age. The ROC graphical curve was plotted to determine the OR2A1-AS1 activity in DLBCL patients and normal control. A cutoff value was calculated. The diagnostic specificity, sensitivity, and area under the curve (AUC) values were found to be the same, i.e., 0.9494 (Figure 3A). Consequently, a cutoff value of = 0.45 was selected for OR2A1-AS1 overexpression. Those with lower OR2A1-AS1 expression have a substantially shorter OS and PFS (p = 0.0058 and 0.0023, accordingly) when matched to patients with an elevated OR2A1-AS1 expression (Figure 3B,C). Next, the OR2A1-AS1 predictive value was examined via various COOC. In the GCB group, low OR2A1-AS1 expression suggested a poor outcome than elevated OR2A1-AS1 expression (OS: p = 0.0223; PFS: p = 0.0036) (Figure 3D,E). Furthermore, in the non-GCB group, patients with lower OR2A1-AS1 expression had the same OS and PFS (p = 0.1886, and 0.9293, respectively) as those with an elevated OR2A1-AS1 expression (Figure 3F,G). In multivariate analysis, the Cox proportional hazards regression (CPHR) revealed that lower OR2A1-AS1 expression was an independent PFS prognostic predictor (p = 0.001) (Tables 3 and 4).

**TABLE 1** Clinical features of DLBCL patients

| Variables                | Number of cases (%) |
|--------------------------|---------------------|
| Age ≥ 60 y               | 45 (45.7)           |
| Male                     | 58 (59.4)           |
| Stage III-IV             | 51 (51.6)           |
| Abnormal LDH level       | 45 (46.1)           |
| Performance state 3–4    | 44 (45.3)           |
| Extramedial involvement ≥2| 20 (20.7)          |
| B symptom                | 42 (42.6)           |
| IPI 3–5                  | 46 (47.3)           |
| GCB                      | 56 (57.4)           |
| Non-GCB                  | 42 (42.6)           |

Abbreviations: GCB, germinal center B-cell-like subtype; IPI, International Prognostic Index; LDH, lactate dehydrogenase.

**TABLE 2** Association of OR2A1-AS1 expression with clinical parameters in DLBCL patients

| Variable                  | Number | High OR2A1-AS1 expression (%) | Low OR2A1-AS1 expression (%) | p value |
|---------------------------|--------|------------------------------|-----------------------------|---------|
| Sex                       |        |                              |                             | 0.842   |
| Male                      | 58     | 27                           | 31                          |         |
| Female                    | 40     | 22                           | 18                          |         |
| Age ≥60 years             | 45     | 23                           | 22                          | 0.746   |
| <60 years                 | 53     | 26                           | 27                          |         |
| B symptoms                |        |                              |                             | <0.05   |
| Present                   | 42     | 13                           | 29                          |         |
| Absent                    | 56     | 36                           | 20                          |         |
| Stage                     |        |                              |                             | <0.05   |
| I-II                      | 47     | 35                           | 12                          |         |
| III-IV                    | 51     | 14                           | 37                          |         |
| Performance status        |        |                              |                             | <0.05   |
| 0–2                       | 54     | 37                           | 17                          |         |
| 3–4                       | 44     | 12                           | 32                          |         |
| CHOP-like treatment       |        |                              |                             | <0.05   |
| Response                  | 44     | 34                           | 10                          |         |
| Nonresponse               | 54     | 15                           | 39                          |         |
| Subtypes                  |        |                              |                             | <0.05   |
| GCB                       | 56     | 16                           | 40                          |         |
| Non-GCB                   | 42     | 33                           | 9                           |         |
| IPI                       |        |                              |                             | <0.05   |
| 0–3                       | 52     | 37                           | 15                          |         |
| 3–5                       | 46     | 12                           | 34                          |         |

Note: A statistically considerable variation was defined as p < 0.05.

Abbreviations: CHOP, cyclophosphamide, rituximab, vincristine, doxorubicin, and prednisone; GCB, germinal center B-cell-like subtype; IPI, International Prognostic Index.
DISCUSSION

The reported studies have revealed the role of LncRNAs in many carcinomas. LncRNAs have been evaluated as potential biomarkers and therapeutic targets for many cancers, such as DLBCL. Herein, we identified lncRNAs that could enhance the diagnostic and prognostic potencies in DLBCL patients. The identified LncRNAs were then determined and confirmed in a variety of specimens, including primary tissues from DLBCL patients, ensuring a high level of accuracy. ROC curves revealed that OR2A1-AS1 was the candidate LncRNA, with high AUC, diagnostic sensitivity, and specificity.

The abnormal expression of specific LncRNAs may indicate the progression of cancer and can serve as key diagnostic and prognostic biomarkers. Zhou et al. indicated some LncRNAs that might have a considerable role in the diagnosis and prediction of DLBCL. However, it is currently unclear whether other LncRNAs can be used as candidate biomarkers in DLBCL. Hence, it is needed to identify novel biomarkers involved in the DLBCL development. One LncRNA can be expressed at varying amounts in different samples and disorders. In the current study, a large sample group was enrolled to evaluate the expression of potential LncRNAs that led to the identification of one considerably varied LncRNA, i.e., OR2A1-AS1.

LncRNA including XLOC_009167, D16366, and PTCSC3 are potential biomarkers that predict lung cancer, hepatocellular cancer, and gastric cancer accordingly. However, the prognostic value of the OR2A1-AS index has barely been identified in DLBCL. In this study, it has been indicated that the group having the low expression of OR2A1-AS had considerably worse outcomes than the group having an elevated expression of OR2A1-AS. Stratification analysis revealed the prognostic value of OR2A1-AS in GCB-DLBCL.
but not in non-GCB-like-DLBCL. OR2A1-AS remained a significant predictive factor of PFS (in DLBCL) in MVA by CPHR. The limitation of this work is that the number of samples is not large enough. In addition, the exact molecular mechanism of OR2A1-AS in GCB-DLBCL needs to be explored in future research.

**5 | CONCLUSION**

The OR2A1-AS index was found to be an effective predictor of patients’ outcomes with DLBCL, particularly in the GCB-DLBCL group. OR2A1-AS was found to be a significant predictor of PFS in DLBCL in MVA. Targeting OR2A1-AS treatments could be a promising method to improve patient’s outcomes in the age of precision medicine.

**CONFLICT OF INTEREST**

No competing interests have been declared by the authors.

**DATA AVAILABILITY STATEMENT**

Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data are not available.
9. Li S, Hao J, Hong Y, Mai J, Huang W. Long non-coding RNA NEAT1 promotes the proliferation, migration, and metastasis of human breast-cancer cells by inhibiting miR-146b-5p expression. *Cancer Manag Res*. 2020;12:6091-6101.

10. Wang P, Hu L, Fu G, et al. LncRNA MALAT1 promotes the proliferation, migration, and invasion of melanoma cells by downregulating miR-23a. *Cancer Manag Res*. 2020;12:6553-6562.

11. Xing C, Sun SG, Yue ZQ, Bai F. Role of LncRNA LUCAT1 in cancer. *Biomed Pharmacother*. 2021;134:111158.

12. Feng Y, Wu M, Hu S, Peng X, Chen F. LncRNA DDX11-AS1: a novel oncogene in human cancer. *Hum Cell*. 2020;33:946-953.

13. Zhao L, Liu Y, Zhang J, Liu Y, Qi Q. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promotes diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. *Cell Death Dis*. 2019;10:731.

14. Wang QM, Lian GY, Song Y, Huang YF, Gong Y. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. *Life Sci*. 2019;231:116335.

15. Qian CS, Li LJ, Huang HW, Yang HF, Wu DP. MYC-regulated LncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma. *Cancer Cell Int*. 2020;20:87.

16. Peng W, Fan H, Wu G, Wu J, Feng J. Upregulation of long non-coding RNA PEG10 and invasion with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. *Clin Exp Med*. 2016;16:177-182.

17. Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. 2007;109:1857-1861.

18. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. and MabThera International Trial G. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. 2007;109:1857-1861.

19. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem*. 2009;55:611-622.

20. Wang J, Su Z, Lu S, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. *Clin Chim Acta*. 2018;485:229-233.

21. Zhang F, Wang H, Yu J, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. *Mol Cancer*. 2021;20:6.

22. Gao H, Wu B, Jin H, Yang W. A 6-lncRNA signature predicts prognosis of diffuse large B-cell lymphoma. *J Biochem Mol Toxicol*. 2021;35:1-12.

23. Sun J, Cheng L, Shi H, et al. A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. *Sci Rep*. 2016;6:27842.

24. Xu P, Chen X, Su P. A pooled analysis of the clinical utilities of long non-coding RNA based molecular signature for diffuse large B cell lymphoma. *Cancer Manag Res*. 2020;12:6553-6562.

25. Wu Z, Liu Y, Wei L, Han M. LncRNA OIP5-AS1 promotes breast cancer progression by regulating miR-216a-5p/GLO1. *J Surg Res*. 2021;257:501-510.

26. Sheng JQ, Wang MR, Fang D, et al. LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma. *Biomed Pharmacother*. 2021;133:111023.

27. Zhou M, Zhao H, Xu W, Bao S, Cheng L, Sun J. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. *Mol Cancer*. 2017;16:16.

28. Jiang N, Meng X, Mi H, et al. Circulating LncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. *Clin Chim Acta*. 2018;486:26-33.

29. Zhao Y, Zhou D. LncRNA D16366 is a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma. *Med Sci Monit*. 2019;25:6581-6586.

30. Zhang G, Chi N, Lu Q, Zhu D, Zhuang Y. LncRNA PTCS2 is a biomarker for the treatment and prognosis of gastric cancer. *Cancer Biother Radiopharm*. 2020;35:77-81.

How to cite this article: Ye S, Ying W, Lin Y, Hou Z, Su M. LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma. *J Clin Lab Anal*. 2022;36:e24680. doi: [10.1002/jcla.24680](https://doi.org/10.1002/jcla.24680)